Siemens Healthineers has received CE-Mark for its ultra-high-field 7T magnetic resonance (MR) scanner Magnetom Terra, making it available for neurological and musculoskeletal clinical examinations in Europe.
Cel-Sci said today that for a Phase III trial of its investigational immunotherapy, it inked an agreement with institutional investors for a $3.5 million registered direct offering.
The adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older has been cleared by the Medicines and Healthcare products Regulatory Agency.
Biotronik has secured approval from the US Food and Drug Admini(FDA) for its Edora HF-T QP, a MR conditional quadripolar (QP) cardiac resynchronization therapy pacemaker (CRT-P).
FDA has cleared Irish life sciences company Malin Corp for its Hourglass peripheral embolization plug.
Cynvenio Biosystems has initiated a clinical study to evaluate its LiquidBiopsy ClearID test in combination with NK Score natural killer cell activity to monitor breast cancer patients in the US.
A five-year strategic research collaboration between AstraZeneca and its global biologics research and development arm MedImmune and Ethris, a company focussed on mRNA-based therapeutics with specific expertise in pulmonary disease.
The ProxiSure laparoscopic suturing device was launched, said Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon.
The 13th Health Asia & Pharma Asia International Exhibition & Conferences (Pharma Asia) will be held at the Karachi Expo Center from August 22nd to August 24th 2017. As the leading global pharmaceutical and medical device B2B online platform, Ddu is going to attend the exhibition along with the products of high priority members.
Pfizer’s Besponsa has been approved by the US Food and Drug Administration (FDA). It's the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.